Skip to Main Content

A rift may have opened in the Alzheimer’s disease partnership between Biogen (BIIB) and its Japanese pharma partner Eisai following the high-profile and costly failure of their jointly developed drug aducanumab.

Eisai said Friday that it intends to push ahead with the development of a second Alzheimer’s drug, called BAN2401, also part of the Biogen partnership. A Phase 3 clinical trial of BAN2401 targeting the enrollment of 1,500 patients with early Alzheimer’s disease has been initiated, Eisai said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Anthony J. Martorell, Abigail L. Paulson, Ho-Jun Suk, Fatema Abdurrob, Gabrielle T. Drummond, Webster Guan, Jennie Z. Young, David Nam-Woo Kim, Oleg Kritskiy, Scarlett J. Barker, Vamsi Mangena, Stephanie M. Prince, Emery N. Brown, Kwanghun Chung, Edward S. Boyden, Annabelle C. Singer, Li-Huei Tsai. Multi-sensory Gamma Stimulation Ameliorates Alzheimer’s-Associated Pathology and Improves Cognition. Cell, 2019; DOI: 10.1016/j.cell.2019.02.014

Comments are closed.